Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
INNV vs ALHC vs OSCR vs ENSG vs CCRN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Care Facilities
Medical - Care Facilities
INNV vs ALHC vs OSCR vs ENSG vs CCRN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $1.10B | $3.73B | $5.41B | $10.18B | $423M |
| Revenue (TTM) | $946M | $4.26B | $13.30B | $5.27B | $761M |
| Net Income (TTM) | $-22M | $20M | $-39M | $363M | $-99M |
| Gross Margin | 14.8% | 9.0% | 17.4% | 15.2% | 18.2% |
| Operating Margin | 1.5% | 0.8% | 0.1% | 8.5% | -0.9% |
| Forward P/E | 32.0x | 140.9x | 34.7x | 23.2x | 133.8x |
| Total Debt | $101M | $338M | $430M | $4.15B | $2M |
| Cash & Equiv. | $64M | $578M | $2.77B | $504M | $109M |
INNV vs ALHC vs OSCR vs ENSG vs CCRN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| InnovAge Holding Co… (INNV) | 100 | 31.3 | -68.7% |
| Alignment Healthcar… (ALHC) | 100 | 83.2 | -16.8% |
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
| The Ensign Group, I… (ENSG) | 100 | 185.7 | +85.7% |
| Cross Country Healt… (CCRN) | 100 | 104.8 | +4.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INNV vs ALHC vs OSCR vs ENSG vs CCRN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INNV is the #2 pick in this set and the best alternative if momentum is your priority.
- +147.9% vs CCRN's -5.4%
ALHC ranks third and is worth considering specifically for growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 46.1% revenue growth vs CCRN's -21.6%
OSCR is the clearest fit if your priority is value.
- Lower P/E (34.7x vs 133.8x)
ENSG carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 12 yrs, beta 0.42, yield 0.1%
- 7.5% 10Y total return vs ALHC's 5.4%
- Beta 0.42, yield 0.1%, current ratio 1.42x
- 6.9% margin vs CCRN's -13.0%
CCRN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (34.7x vs 133.8x) | |
| Quality / Margins | 6.9% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.42 vs OSCR's 1.84 | |
| Dividends | 0.1% yield; 12-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +147.9% vs CCRN's -5.4% | |
| Efficiency (ROA) | 6.8% ROA vs CCRN's -19.8%, ROIC 7.0% vs -0.9% |
INNV vs ALHC vs OSCR vs ENSG vs CCRN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INNV vs ALHC vs OSCR vs ENSG vs CCRN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ENSG leads in 2 of 6 categories
CCRN leads 1 • INNV leads 0 • ALHC leads 0 • OSCR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — OSCR and ENSG each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OSCR is the larger business by revenue, generating $13.3B annually — 17.5x CCRN's $761M. ENSG is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, OSCR holds the edge at +52.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $946M | $4.3B | $13.3B | $5.3B | $761M |
| EBITDAEarnings before interest/tax | $4M | $66M | $40M | $558M | $9M |
| Net IncomeAfter-tax profit | -$22M | $20M | -$39M | $363M | -$99M |
| Free Cash FlowCash after capex | $39M | $237M | $2.8B | $406M | $41M |
| Gross MarginGross profit ÷ Revenue | +14.8% | +9.0% | +17.4% | +15.2% | +18.2% |
| Operating MarginEBIT ÷ Revenue | +1.5% | +0.8% | +0.1% | +8.5% | -0.9% |
| Net MarginNet income ÷ Revenue | -2.3% | +0.5% | -0.3% | +6.9% | -13.0% |
| FCF MarginFCF ÷ Revenue | +4.1% | +5.6% | +21.0% | +7.7% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.5% | +33.3% | +52.6% | +18.4% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -161.3% | +2.1% | +125.0% | +21.9% | -6.0% |
Valuation Metrics
CCRN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CCRN's 23.7x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.1B | $3.7B | $5.4B | $10.2B | $423M |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $3.5B | $3.1B | $13.8B | $317M |
| Trailing P/EPrice ÷ TTM EPS | -36.73x | -4932.43x | -12.35x | 29.85x | -4.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.03x | 140.93x | 34.65x | 23.19x | 133.84x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.16x | — |
| EV / EBITDAEnterprise value multiple | — | 77.12x | — | 25.71x | 23.75x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | 0.94x | 0.46x | 2.01x | 0.40x |
| Price / BookPrice ÷ Book value/share | 4.16x | 20.16x | 5.58x | 4.59x | 1.31x |
| Price / FCFMarket cap ÷ FCF | 41.22x | 32.95x | 5.11x | 27.46x | 10.55x |
Profitability & Efficiency
ENSG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), INNV scores 6/9 vs OSCR's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -8.2% | +11.5% | -3.3% | +16.6% | -27.1% |
| ROA (TTM)Return on assets | -4.1% | +1.8% | -0.6% | +6.8% | -19.8% |
| ROICReturn on invested capital | -6.8% | — | — | +7.0% | -0.9% |
| ROCEReturn on capital employed | -7.1% | +2.9% | -25.3% | +10.2% | -0.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.38x | 1.89x | 0.44x | 1.86x | 0.01x |
| Net DebtTotal debt minus cash | $37M | -$240M | -$2.3B | $3.7B | -$106M |
| Cash & Equiv.Liquid assets | $64M | $578M | $2.8B | $504M | $109M |
| Total DebtShort + long-term debt | $101M | $338M | $430M | $4.2B | $2M |
| Interest CoverageEBIT ÷ Interest expense | 5.96x | 1.27x | -0.57x | 88.33x | -1.39x |
Total Returns (Dividends Reinvested)
Evenly matched — OSCR and ENSG each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ENSG five years ago would be worth $20,324 today (with dividends reinvested), compared to $3,150 for INNV. Over the past 12 months, INNV leads with a +147.9% total return vs CCRN's -5.4%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +55.7% | -9.7% | +39.4% | +0.3% | +62.4% |
| 1-Year ReturnPast 12 months | +147.9% | +17.6% | +22.6% | +27.5% | -5.4% |
| 3-Year ReturnCumulative with dividends | +24.5% | +152.4% | +177.5% | +88.9% | -44.3% |
| 5-Year ReturnCumulative with dividends | -68.5% | -22.7% | -7.3% | +103.2% | -22.5% |
| 10-Year ReturnCumulative with dividends | -66.6% | +5.4% | -40.0% | +752.0% | -10.5% |
| CAGR (3Y)Annualised 3-year return | +7.6% | +36.2% | +40.5% | +23.6% | -17.7% |
Risk & Volatility
Evenly matched — OSCR and ENSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ENSG is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSCR currently trades 87.7% from its 52-week high vs INNV's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.66x | 0.75x | 1.84x | 0.42x | 0.78x |
| 52-Week HighHighest price in past year | $10.68 | $23.87 | $23.80 | $218.00 | $14.99 |
| 52-Week LowLowest price in past year | $2.85 | $11.63 | $10.69 | $133.81 | $7.43 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +76.5% | +87.7% | +80.0% | +87.3% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 37.3 | 78.5 | 23.3 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 291K | 3.6M | 6.5M | 358K | 552K |
Analyst Outlook
ENSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: INNV as "Hold", ALHC as "Buy", OSCR as "Hold", ENSG as "Buy", CCRN as "Hold". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs -19.7% for OSCR (target: $17). ENSG is the only dividend payer here at 0.14% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $6.80 | $24.83 | $16.75 | $222.33 | $10.61 |
| # AnalystsCovering analysts | 8 | 16 | 11 | 13 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.1% | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | 12 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $0.24 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | 0.0% | +0.2% | +1.6% |
ENSG leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). CCRN leads in 1 (Valuation Metrics). 3 tied.
INNV vs ALHC vs OSCR vs ENSG vs CCRN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INNV or ALHC or OSCR or ENSG or CCRN a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). The Ensign Group, Inc. (ENSG) offers the better valuation at 29. 8x trailing P/E (23. 2x forward), making it the more compelling value choice. Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INNV or ALHC or OSCR or ENSG or CCRN?
On forward P/E, The Ensign Group, Inc.
is actually cheaper at 23. 2x.
03Which is the better long-term investment — INNV or ALHC or OSCR or ENSG or CCRN?
Over the past 5 years, The Ensign Group, Inc.
(ENSG) delivered a total return of +103. 2%, compared to -68. 5% for InnovAge Holding Corp. (INNV). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus INNV's -66. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INNV or ALHC or OSCR or ENSG or CCRN?
By beta (market sensitivity over 5 years), The Ensign Group, Inc.
(ENSG) is the lower-risk stock at 0. 42β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 336% more volatile than ENSG relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INNV or ALHC or OSCR or ENSG or CCRN?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INNV or ALHC or OSCR or ENSG or CCRN?
The Ensign Group, Inc.
(ENSG) is the more profitable company, earning 6. 8% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 6. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENSG leads at 8. 6% versus -3. 5% for INNV. At the gross margin level — before operating expenses — INNV leads at 68. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INNV or ALHC or OSCR or ENSG or CCRN more undervalued right now?
On forward earnings alone, The Ensign Group, Inc.
(ENSG) trades at 23. 2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 117. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.
08Which pays a better dividend — INNV or ALHC or OSCR or ENSG or CCRN?
In this comparison, ENSG (0.
1% yield) pays a dividend. INNV, ALHC, OSCR, CCRN do not pay a meaningful dividend and should not be held primarily for income.
09Is INNV or ALHC or OSCR or ENSG or CCRN better for a retirement portfolio?
For long-horizon retirement investors, The Ensign Group, Inc.
(ENSG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), +752. 0% 10Y return). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ENSG: +752. 0%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INNV and ALHC and OSCR and ENSG and CCRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INNV is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock; OSCR is a small-cap high-growth stock; ENSG is a mid-cap high-growth stock; CCRN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.